MBCProject_0734_T1K_RNA
— · C
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- C
- subtype
- C
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.690
- INTERFERON_GAMMA_RESPONSE+0.610
- ALLOGRAFT_REJECTION+0.530
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.530
- INFLAMMATORY_RESPONSE+0.530
- COMPLEMENT+0.450
- IL6_JAK_STAT3_SIGNALING+0.450
- KRAS_SIGNALING_UP+0.420
- PROTEIN_SECRETION+0.410
- TNFA_SIGNALING_VIA_NFKB+0.390
Top 10 suppressed
- WNT_BETA_CATENIN_SIGNALING-0.200
- PEROXISOME-0.180
- BILE_ACID_METABOLISM-0.170
- NOTCH_SIGNALING-0.160
- ESTROGEN_RESPONSE_EARLY-0.070
- ADIPOGENESIS-0.040
- HEDGEHOG_SIGNALING-0.040
- OXIDATIVE_PHOSPHORYLATION-0.040
- G2M_CHECKPOINT-0.020
- MYC_TARGETS_V2-0.010
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
6 twins match this tumor's tissue · 4 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | MBCProject_0734_T1B_RNA | — | C | 0.909 |
| 2 | SRR10900560 | — | — | 0.899 |
| 3 | BS_1JDG6JV5 | pilocytic astrocytoma | — | 0.894 |
| 4 | SRR1516052 | — | — | 0.886 |
| 5 | BS_7H4RFCW9 | low-grade glioma | — | 0.880 |
| 6 | AUR-AFEC-TTM6-A-1-1-R-A742-41 | — | C | 0.878 |
| 7 | SRR6013494 | — | cohortA1 | 0.878 |
| 8 | BS_850BAHH9 | ATRT | — | 0.877 |
| 9 | f62519fa-7479-4e20-9ae4-d57f8a1e0e64 | — | — | 0.877 |
| 10 | s_150324_4b | EPN | Posterior Fossa EPN | 0.875 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 39 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.690 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.610 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.530 | Idelalisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.530 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.530 | Idelalisib | — uncovered |
| COMPLEMENT | 0.450 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.450 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.420 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.410 | Remibrutinib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.390 | Inavolisib | — uncovered |
| APOPTOSIS | 0.380 | Idelalisib | — uncovered |
| ANGIOGENESIS | 0.370 | Remibrutinib | — uncovered |
| COAGULATION | 0.370 | Binimetinib | — uncovered |
| IL2_STAT5_SIGNALING | 0.360 | Idelalisib | — uncovered |
| APICAL_JUNCTION | 0.290 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.290 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.290 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.280 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.260 | Idelalisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.220 | Remibrutinib | — uncovered |